Biosimilars Pipeline

About Intelligent Therapeutics

Intelligent Therapeutics is a private, preclinical-stage biotech leveraging novel molecular engineering approaches to develop therapeutics for oncology and autoimmune diseases. The company operates a dual pipeline encompassing innovative biologics and biosimilars, indicating a strategy to balance high-risk innovation with lower-risk development. While appearing to be pre-revenue and early-stage, its focus on antibody engineering and expansion into veterinary health presents a diversified approach within the biotech sector.

About Alkem Laboratories

Founded in 1973, Alkem Laboratories has grown from a domestic manufacturer into a globally recognized pharmaceutical company with a mission to deliver trusted, affordable healthcare through innovation and quality. Its strategic pillars include a deep focus on complex generics and novel drug delivery systems, a sprawling international footprint, and a diversified portfolio across key therapeutic areas like anti-infectives, cardiology, and gastroenterology. The company's success is underpinned by its aggressive patent challenge strategy in regulated markets like the US, a vast network of 18 manufacturing facilities, and a strong commercial engine driving growth in both emerging and developed markets.

About Jubilant Pharmova

Jubilant Pharmova's mission is to become a leading global pharmaceutical company by delivering high-quality, affordable medicines through innovation and operational excellence. The company has achieved this through strategic vertical integration, building world-class manufacturing assets for complex APIs and sterile injectables, and establishing a strong global footprint. Its core strategy focuses on deepening capabilities in high-growth specialty segments like oncology and radiopharmaceuticals, while expanding its high-margin Contract Development and Manufacturing (CDMO) business to leverage global outsourcing trends.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals is a revenue-generating, publicly traded pharmaceutical company with a mission to improve global access to high-quality medicines. It operates through three distinct, market-leading segments: a top-five global Injectables business, a rapidly growing US-focused Generics (Hikma Rx) division, and a Branded business that is the largest pharmaceutical company by sales in the MENA region. The company's strategy focuses on striving for operational excellence, diversifying its product pipeline, and empowering its people, supported by a culture of innovation, caring, and collaboration. Recent achievements include launching 84 products in 2025 and implementing strategic investments to drive future growth.

Therapeutic Areas

Other Undisclosed Drugs